



About us ▾

Living Mapping ▾

Living evidence synthesis ▾

Vaccines ▾

Data sharing ▾




As of **January 20, 2021** the **Covid-19 - living NMA initiative** collected **150 RCTs** and **36 non-randomised studies of vaccines** from the **ICTRP**. **93** of these trials are recruiting patients.

▼ User Guide 📖

- To see how to explore the mapping, check [our tutorial](#).
- Make your browser window as **wide** as possible for a 2-column display.
- Click on the **map** or any of the **graphs** to create filters on the data.
- All the **filters** are applied jointly, refining your selection.
- Click **Reset all** to remove the filters.
- Click on the **arrows** to open or close any section.
- *For any questions or remarks, please [contact us](#).*

▼ Map



▼ Table

Show full table

Vaccine (per arm)	Sample size	Type of vaccine	Phase	Sponsor/Funder	Reg. number
(1) ChAdOx1 nCoV-19 vaccine	12390	Non replicating viral vector	Phase 2 / Phase 3	University of Oxford	NCT04400838
(1) LNP-nCoVsaRNA vs (2) LNP-nCoVsaRNA vs (3) LNP-nCoVsaRNA	320	RNA based vaccine	Phase 1	1. Medical Research Council (UK) 2. UK Research and Innovation (UK)	ISRCTN17072692
(1) SARS-CoV-2 vaccine vs (2) SARS-CoV-2 vaccine vs (3) SARS-CoV-2 vaccine	942	Inactivated virus	Phase 1 / Phase 2	Chinese Academy of Medical Sciences	NCT04412538
(1) ChAdOx1 nCoV-19 vaccine	10300	Non replicating viral vector	Phase 3	University of Oxford	ISRCTN89951424
(1) Ad26COVS1 vs (2) Ad26COVS1 vs (3) Ad26COVS1	1045	Non replicating viral vector	Phase 1 / Phase 2	Janssen Vaccines & Prevention B.V.	NCT04436276
(1) ChAdOx1 nCoV-19 vaccine vs (2) ChAdOx1 nCoV-19 vaccine vs (3) ChAdOx1 nCoV-19 vaccine vs (4) ChAdOx1 nCoV-19 vaccine	2130	Non replicating viral vector	Phase 1 / Phase 2	University of Witwatersrand, South Africa	NCT04444674
(1) GX-19 vs (2) GX-19 vs (3) GX-19	210	DNA based vaccine	Phase 1 / Phase 2	Genexine, Inc.	NCT04445389
(1) CVnCoV Vaccine	280	RNA based vaccine	Phase 1	CureVac AG	NCT04449276
(1) SARS-CoV-2 mRNA vaccine vs (2) SARS-CoV-2 mRNA vaccine vs (3) SARS-CoV-2 mRNA vaccine	168	RNA based vaccine	Phase 1	Shulan (Hangzhou) Hospital; Center for Disease Control and Prevention of Guangxi Zhuang Autonomous Region	ChiCTR2000034112
(1) Covid-19/aAPC vaccine vs (2) Covid-19/aAPC vaccine	100	Viral vector (Non-replicating) + APC (antigen presenting cell)	Phase 1	Shenzhen Geno-Immune Medical Institute	NCT04299724
(1) Recombinant Novel Coronavirus (2019-nCoV) Vaccine (Adenovirus Vector) vs (2) Recombinant Novel Coronavirus (2019-nCoV) Vaccine (Adenovirus Vector) vs (3) Recombinant Novel Coronavirus (2019-nCoV) Vaccine (Adenovirus Vector)	108	Non replicating viral vector	Phase 1	Jiangsu Provincial Center for Disease Control and Prevention	ChiCTR2000030906

Filters

All trials selected (186) |


Reset all

(1) LV-SMENP-DC vaccine	100	Viral vector (Non-replicating) + APC (antigen presenting cell)	Phase 1 / Phase 2	Shenzhen Geno-Immune Medical Institute	NCT04276896
(1) mRNA-1273 vs (2) mRNA-1273 vs (3) mRNA-1273 vs (4) mRNA-1273 vs (5) mRNA-1273	120	RNA based vaccine	Phase 1	National Institute of Allergy and Infectious Diseases (NIAID)	NCT04283461
(1) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) vs (2) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) vs (3) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	108	Non replicating viral vector	Phase 1	CanSino Biologics Inc.	NCT04313127
(1) ChAdOx1 nCoV-19 vaccine vs (2) ChAdOx1 nCoV-19 vaccine vs (3) ChAdOx1 nCoV-19 vaccine vs (4) ChAdOx1 nCoV-19 vaccine vs (5) ChAdOx1 nCoV-19 vaccine vs (6) ChAdOx1 nCoV-19 vaccine+paracetamol	1090	Non replicating viral vector	Phase 1 / Phase 2	University of Oxford	NCT04324606
(1) INO-4800+electroporation vs (2) INO-4800+electroporation vs (3) INO-4800+electroporation	120	DNA based vaccine	Phase 1	Inovio Pharmaceuticals	NCT04336410

Search...

Ex: RNA, Adenovirus, Oxford...

▼ Registration date by week



To filter by Registration dates, click and drag to create a range.

▼ Recruitment status

- Recruiting (93 studies)
- Not recruiting (85 studies)
- Completed (6 studies)
- Not Recruiting (1 study)
- Suspended (1 study)


▼ Publication status

- Not published (167 studies)
- Published (19 studies)


▼ Registry status

- No results posted (186 studies)


▼ Phase




▼ Type of vaccine



▼ Type of patients




▼ Design



▼ Center

▼ Study design



▼ Options

- Zoom & pan the map
- Show number of patients

▼ Credits

Data: COVID-19 - living NMA initiative

Visualisations: Romain Vuillemot - LIRIS, École Centrale de Lyon; Philippe Rivière - LIRIS, VisionsCarto; Pierre Ripoll - LIRIS, INSA Lyon; Julien Barnier - Centre Max Weber, CNRS.

Dashboard developed with DC.js on Observable.